Prevalence of Subclinical Vertebral Fractures in Rheumatoid Arthritis and Ankylosing Spondylitis

Prevalence of Subclinical Vertebral Fractures in Rheumatoid Arthritis and Ankylosing Spondylitis in Egyptian Patients and Its Relation to Some Clinical Data

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06092775

Enrollment

Registered

2023-10-23

Start date

2023-12-31

Completion date

2025-01-31

Last updated

2023-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vertebral Fracture

Brief summary

Study of prevalence of subclinical vertebral fractures in Rheumatoid Arthritis and Ankylosing spondylitis

Detailed description

Detection of the prevalence of subclinical vertebral fractures in Rheumatoid Arthritis and Ankylosing spondylitis Study the relation between vertebral fractures and some clinical data like demographics data, disease duration and disease severity

Interventions

DEVICEDEXA scan,X_ray

DEXA scan detect osteoporosis ,X\_ray show subclinical vertebral fractures

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients fulfilling ACR/EULAR 2010 rheumatoid arthritis classification criteria. Patients diagnosed as ankylosing spondylitis according to ASAS criteria (2000). Age (18-50).

Exclusion criteria

* Patient with other autoimmune Rheumatic disease other than RA and AS. Infections including hepatitis C or B, HIV, tuberculosis. RA and AS patients with known vertebral fractures. Malignancy, hypogonadism, thyroid problems, chronic kidney disease, Hypoparathyroidism, Type 1 DM. Pregnancy and breast-feeding.

Design outcomes

Primary

Measure	Time frame	Description
Comparison of prevalence of subclinical vertebral fractures in RA ,AS and control group	Baseline	Detection of prevalence of subclinical vertebral fractures in RA, AS and control group

Contacts

Primary ContactBASMA NAGEH, RD

bbsam6883@gmail.com01070664417

Backup ContactSAFAA MAHRAN, Prof

safaa.mahran@aun.edu.eg01003385106

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026